Rare Disease Peptide Clinical Trial Challenges

Peptide Gene Therapy and Rare Disease

38 patients

Total enrollment in the phase 3 trial of setmelanotide for Bardet-Biedl syndrome, a rare genetic obesity disorder affecting roughly 1 in 140,000 people.

Haqq et al., Lancet Diabetes Endocrinol, 2022

Haqq et al., Lancet Diabetes Endocrinol, 2022

View as image

Running a clinical trial for a disease that affects 200,000 people is hard. Running one for a disease that affects 2,000 people, using a peptide drug that degrades in the gut and requires injection, is a different category of difficulty. Peptide therapeutics account for roughly 10% of FDA-approved rare disease drugs, and every one of those approvals navigated obstacles that would have killed a conventional trial program.^[1] This article covers what makes these trials so difficult to design, recruit, and run. For the broader landscape of how rare diseases drive peptide innovation, see our pillar article on peptide gene therapy and rare disease.

The Patient Pool Problem

More than 7,000 rare diseases have been identified. A disease qualifies as "rare" under U.S. law when it affects fewer than 200,000 Americans. Many affect fewer than 1,000. When you combine a rare disease with a specific genetic subtype, the eligible trial population can shrink to dozens of patients scattered across multiple continents.

The setmelanotide program illustrates this directly. Setmelanotide is a melanocortin-4 receptor (MC4R) agonist peptide approved for severe obesity caused by specific genetic mutations in the leptin-melanocortin pathway. The phase 3 trial for POMC and LEPR deficiency obesity enrolled 10 and 11 patients, respectively, across ten hospitals in seven countries.^[2] The later Bardet-Biedl syndrome trial enrolled 38 patients across 12 sites in five countries.^[3]

These sample sizes are not accidental. They represent exhaustive global recruitment efforts. POMC deficiency obesity affects an estimated 1 in 1,000,000 people. There are not enough patients on Earth to run a conventional 500-person randomized controlled trial.

Small sample sizes create cascading statistical problems. Studies lack power to detect anything but very large treatment effects. Confidence intervals are wide. A single patient dropout can shift the entire result. The standard statistical framework built for large populations (p-values, Type I/II error rates, multiple comparison corrections) does not translate cleanly to N=38.

The Endpoint Problem

Before you can test whether a drug works, you need to define what "works" means. In common diseases, validated endpoints and established clinical outcome measures have been refined over decades. In rare diseases, they often do not exist.

Teduglutide, a GLP-2 analog approved for short bowel syndrome (SBS), faced this directly. SBS patients depend on parenteral nutrition (PN) after surgical bowel resection. The clinical goal is reducing or eliminating PN dependence. But there was no standardized way to measure "intestinal rehabilitation."^[4]

The teduglutide team developed a "fluid composite effect" as their primary endpoint, combining three measurements: reduction in PN volume, increase in urine production, and reduction in oral fluid intake. This composite reflected the drug's actual physiological effect (increased intestinal fluid absorption) but had never been used before.^[5] Convincing regulators to accept a novel composite endpoint required substantial natural history data and a clear mechanistic rationale linking the endpoint to meaningful patient benefit.

The FDA recognized this gap systemically. Its Rare Disease Endpoint Advancement (RDEA) pilot program, launched in October 2022, conducts up to four meetings with selected sponsors specifically to develop novel endpoints for rare disease trials.^[6] The program gives preference to proposals with broader impact across multiple rare diseases and those using novel approaches for clinical data collection.

Trial Design Constraints

Single-arm and open-label designs

Between 2006 and 2012, rare disease trials were more likely to be single-arm, nonrandomized, and open-label compared to non-rare disease trials.^[7] This reflects both practical necessity and ethical considerations.

When there are 10 eligible patients worldwide, randomizing half to placebo for a year raises ethical questions that do not arise in a 5,000-person cardiovascular outcomes trial. The setmelanotide POMC/LEPR trial used a single-arm, open-label design with a built-in placebo withdrawal period: patients who responded to 12 weeks of open-label treatment entered an 8-week blinded sequence alternating between setmelanotide and placebo.^[2] This design let every patient access the active drug while still generating placebo-controlled data.

The Bardet-Biedl syndrome trial used a more conventional 14-week double-blind, placebo-controlled period followed by a 52-week open-label extension.^[3] The slightly larger patient population (38 vs. 21) made a parallel-group design feasible, though still underpowered by conventional standards.

Adaptive and seamless designs

Adaptive seamless designs combine phase II dose-finding with phase III confirmatory testing in a single protocol, using pre-planned interim analyses to drop ineffective doses and reallocate enrollment.^[7] For rare diseases, this avoids the sample size waste of running separate trials sequentially.

For peptide drugs specifically, adaptive designs help address the dose-finding challenge. Peptides often have narrow therapeutic windows and nonlinear pharmacokinetics. Running a dedicated phase II dose-ranging study in 60 patients is straightforward for a GLP-1 agonist with millions of potential users. It is impractical for a condition affecting 500 people.

Historical and external controls

When natural history data is available, rare disease trials can use external control arms, comparing treated patients to documented disease trajectories in untreated patients. This eliminates the need for a concurrent placebo group.

Pasireotide for Cushing's disease, a rare endocrine disorder caused by pituitary tumors, used this approach in part. The clinical trial program benchmarked outcomes against the known progressive course of untreated Cushing's, where prolonged hypercortisolism causes cardiovascular disease, osteoporosis, and increased mortality.^[8]

The Natural History Catch-22

Effective trial design for rare diseases requires natural history studies that document the untreated course of the disease: its progression rate, variability, key milestones, and biomarker trajectories. But natural history studies themselves require patient identification, consent, longitudinal follow-up, and funding.

For ultra-rare diseases, a natural history study might take 5-10 years and cost millions of dollars before a single drug candidate enters the clinic. This creates a strategic dilemma: invest heavily in characterizing the disease before developing a drug, or develop the drug and design the trial simultaneously, accepting greater regulatory uncertainty.

The FDA has signaled increasing flexibility here, stating it "may be willing to accept greater uncertainty or risk in certain cases, such as for the treatment of serious diseases where there is unmet medical need."^[6] In practice, this means accepting smaller studies, novel endpoints, and less conventional designs when the disease is severe and no treatment exists.

Peptide-Specific Challenges

Beyond the general rare disease trial problems, peptide drugs add their own layer of complexity.

Stability and delivery

Most therapeutic peptides require injection because they are degraded by gastrointestinal proteases and have poor oral bioavailability. For rare disease patients who may be children, cognitively impaired, or receiving treatment for decades, injection burden matters. Setmelanotide requires daily subcutaneous injection. Teduglutide requires daily subcutaneous injection. Octreotide LAR, used for neuroendocrine tumors, requires monthly intramuscular injection at a clinic.

The CLARINET trial of lanreotide for metastatic neuroendocrine tumors managed this by using a deep subcutaneous depot formulation given every 28 days, reducing injection frequency.^[9] But injection site reactions remain among the most common adverse events in peptide rare disease trials. In the setmelanotide POMC trial, all 10 patients reported injection site reactions.^[2]

Immunogenicity

Peptide drugs can trigger anti-drug antibody formation, particularly with repeated long-term dosing. In small patient populations, even one or two patients developing neutralizing antibodies can confound efficacy analyses. Immunogenicity testing requirements add cost and complexity to already expensive programs, and the small sample sizes make it difficult to characterize the incidence and clinical impact of anti-drug antibodies.

Manufacturing for tiny markets

Peptide synthesis is more expensive per dose than small molecule production. For a rare disease peptide serving hundreds or low thousands of patients, the manufacturing economics are challenging. Good Manufacturing Practice (GMP) production runs must meet the same regulatory standards regardless of batch size, but the fixed costs are spread across far fewer units.

The Orphan Drug Incentive Structure

The Orphan Drug Act of 1983 created financial incentives specifically designed to offset these challenges. Sponsors receive tax credits for clinical trial costs, a waiver of the Prescription Drug User Fee Act (PDUFA) application fee (over $3.5 million in 2025), and seven years of marketing exclusivity upon approval.^[10]

These incentives have driven substantial investment. The orphan drug market exceeded $242 billion in 2024, and orphan-designated drugs now account for a disproportionate share of FDA approvals. Between 2015 and 2024, 47 drugs were approved for rare genetic disorders.^[1]

For peptide developers, the seven-year exclusivity is particularly valuable because it protects against generic (or biosimilar) competition during the period when the small market must recoup development costs. Without it, many rare disease peptide programs would be economically unviable.

Recruitment Barriers

Even when a trial is designed and funded, filling enrollment targets presents its own challenges.^[7]

Geographic dispersion. Patients with ultra-rare diseases are spread globally. The setmelanotide trials required sites across five to seven countries. Travel to a trial site may require international flights, hotel stays, and weeks away from home, repeated for each visit. This disproportionately excludes patients with limited financial resources.

Diagnostic delay. Many rare diseases take years to diagnose. The average diagnostic odyssey for a rare disease patient is 4-7 years. Patients who have not yet received a genetic diagnosis cannot be recruited. For peptide drugs targeting specific genetic mutations (like setmelanotide's requirement for confirmed POMC, PCSK1, or LEPR variants), genetic testing is a prerequisite that further narrows the pool.

Pediatric populations. Many genetic rare diseases manifest in childhood, requiring pediatric trial expertise, age-appropriate formulations, and additional ethical review. Setmelanotide's trials included patients as young as 6 years old. Pediatric enrollment adds consent complexity (parental consent, minor assent) and requires pediatric pharmacokinetic data.

Competing trials. When multiple companies pursue treatments for the same rare disease, they compete for the same small pool of eligible patients. This can slow enrollment for all programs simultaneously.

Case Studies in Success

Despite these obstacles, several peptide rare disease programs have reached approval.

The octreotide PROMID trial for midgut neuroendocrine tumors randomized 85 patients and demonstrated significantly prolonged time to tumor progression (14.3 months vs. 6.0 months with placebo).^[11] The lanreotide CLARINET trial enrolled 204 patients with metastatic enteropancreatic neuroendocrine tumors and showed significantly improved progression-free survival (median not reached vs. 18 months with placebo).^[9] These neuroendocrine tumor trials benefited from a relatively "less rare" indication (incidence ~5 per 100,000), established diagnostic criteria, and tumor progression as a validated endpoint.

At the other extreme, setmelanotide's approval for POMC and LEPR deficiency required single-arm trials in 10-11 patients with a novel withdrawal design, demonstrating the FDA's willingness to accept unconventional evidence when the unmet need is clear and the treatment effect is large (80% of POMC-deficient patients achieved at least 10% weight loss).^[2]

Where the Field Is Headed

Several trends are reshaping rare disease peptide trial design. AI-driven patient identification tools are scanning electronic health records and genetic databases to find undiagnosed patients who might qualify for trials. Decentralized trial designs are reducing the travel burden by allowing remote monitoring and home-based dosing. The FDA's RDEA program is building a library of validated endpoints that future programs can adopt rather than developing from scratch.

For peptide drugs specifically, advances in delivery (depot formulations, oral peptide technology, and long-acting conjugates) are reducing injection frequency and improving patient retention. These are incremental improvements, not transformative ones. The fundamental tension, between the statistical demands of rigorous evidence generation and the biological reality of diseases that affect very few people, remains the central challenge.

The Bottom Line

Rare disease peptide clinical trials face compounding challenges: patient populations too small for conventional trial designs, missing endpoints that must be developed from scratch, injection-based delivery that creates adherence barriers, and manufacturing economics that strain commercial viability. Regulatory incentives (orphan drug designation, RDEA pilot program) and innovative trial designs (adaptive seamless, placebo-controlled withdrawal, external controls) have enabled approvals like setmelanotide and teduglutide, but each program required creative solutions to problems that do not arise in large-market drug development.

Frequently Asked Questions

How many patients are typically in a rare disease peptide clinical trial?

Enrollment varies widely depending on disease prevalence. The setmelanotide phase 3 trials for POMC and LEPR deficiency enrolled 10-11 patients each. The Bardet-Biedl syndrome trial enrolled 38. Somatostatin analog trials for neuroendocrine tumors enrolled 85-204, reflecting a higher disease incidence. FDA guidance acknowledges that smaller trials may be acceptable for rare diseases with unmet medical need, though this increases the uncertainty around efficacy and safety estimates.

Why don't rare disease trials use randomized placebo-controlled designs?

Some do, particularly when the patient population is large enough. But for ultra-rare diseases with severe symptoms, randomizing patients to placebo for extended periods raises ethical concerns. Many rare disease peptide trials use alternative designs: single-arm with external controls, crossover designs where every patient eventually receives the drug, or placebo-controlled withdrawal periods embedded within open-label treatment phases.

What is orphan drug designation and why does it matter for peptide drugs?

Orphan drug designation is granted by the FDA for drugs targeting diseases affecting fewer than 200,000 Americans. It provides tax credits for clinical trial costs, waiver of the PDUFA application fee (over $3.5 million), and seven years of market exclusivity upon approval. For peptide developers, the exclusivity period is critical because it protects against competition while the small patient market generates revenue to recoup development costs.

What are the biggest challenges specific to peptide drugs in rare disease trials?

Peptides add three layers of difficulty beyond the general rare disease trial challenges. First, most require injection because they are destroyed in the gut, creating an adherence burden for patients who may need lifelong treatment. Second, repeated peptide dosing can trigger anti-drug antibodies that reduce efficacy, and small trial sizes make it hard to characterize this risk. Third, GMP peptide manufacturing is expensive per dose, and the economics are strained when the total addressable market is hundreds of patients.

How does the FDA handle evidence standards for rare disease drugs?

The FDA has stated it may accept "greater uncertainty or risk" for treatments addressing serious unmet medical needs. In practice, this translates to accepting smaller sample sizes, novel endpoints, single-arm designs, and surrogate biomarkers that would not be sufficient for common diseases. The RDEA pilot program specifically supports novel endpoint development, and the agency conducts pre-submission meetings to align on trial design before sponsors commit resources.

What rare disease peptide drugs are currently FDA-approved?

Approved peptide drugs for rare diseases include setmelanotide (POMC, LEPR, and BBS-related obesity), teduglutide (short bowel syndrome), octreotide and lanreotide (neuroendocrine tumors), pasireotide (Cushing's disease), and teriparatide (severe osteoporosis). Each followed a different development path reflecting the specific challenges of its target disease and patient population.